Replies to post #4070 on RespireRx Pharmaceuticals Inc (fka RSPI)

[neuroinv]

Oldies:
I don't think the bicifadine idea was at all related to some hypothetical side effect from high-impacts. It was due to fact bicifadine is in PhIII, endpoints are measurable and trials are relatively short. That was the appeal, IMHO.

NeuroInvestment